Shares of LianBio (NASDAQ:LIAN – Get Free Report) shot up 2.5% during trading on Friday . The company traded as high as $0.30 and last traded at $0.30. 175,223 shares changed hands during trading, a decline of 83% from the average session volume of 1,037,083 shares. The stock had previously closed at $0.29.
LianBio Stock Performance
The stock’s 50-day moving average price is $0.31 and its two-hundred day moving average price is $0.31. The stock has a market capitalization of $32.42 million, a PE ratio of -0.37 and a beta of 0.23.
About LianBio
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.
Read More
- Five stocks we like better than LianBio
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- 3 Best Fintech Stocks for a Portfolio Boost
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for LianBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LianBio and related companies with MarketBeat.com's FREE daily email newsletter.
